基于mpMRI肿瘤位置与克隆源密度的前列腺IMRT体素级生物学优化
本研究构建了基于多参数MRI(mpMRI)获取患者特异性肿瘤位置与克隆源密度的前列腺IMRT生物学优化框架,对5例前列腺癌患者分别采用均匀剂量计划和概率生物学优化计划进行对比。结果显示生物学优化在维持肿瘤控制概率的同时,平均降低直肠等效均匀剂量38.6%(P<0.01)、膀胱等效均匀剂量51.2%(P<0.01)。
要点
- 基于mpMRI的体素级生物学优化在前列腺IMRT中可行。
- 生物学优化计划平均降低直肠EUD 38.6%、膀胱EUD 51.2%。
- 在几何不确定性下仍可维持稳健的肿瘤控制。
核心结论
- 基于患者克隆源分布调整前列腺内剂量分布是可行的,可在不牺牲局部控制的前提下降低正常组织毒性。
研究设计与样本
- 规划研究,对5例前列腺癌患者生成IMRT计划,比较均匀剂量规划与以临床靶区肿瘤控制概率最大化为目标的概率生物学优化。
主要发现
- 生物学优化可将剂量分布塑形至肿瘤特征空间分布,在不牺牲局部控制的情况下潜在降低正常组织毒性。
- 与均匀剂量计划相比,生物学优化计划平均降低直肠等效均匀剂量38.6%(P<0.01)。
- 与均匀剂量计划相比,生物学优化计划平均降低膀胱等效均匀剂量51.2%(P<0.01)。
关键数值与推荐
- 患者特异性肿瘤位置与克隆源密度信息来自mpMRI,几何不确定性纳入TCP计算。
- 在等效预期肿瘤控制水平下比较均匀剂量计划与生物学优化计划的剂量指标。
临床怎么用
- 可利用mpMRI衍生的肿瘤空间生物学信息进行个体化IMRT剂量塑形,在维持肿瘤控制的同时降低直肠和膀胱剂量。
- 计划设计需考虑几何不确定性以保持稳健性,并关注适应性治疗与尿道剂量限制。
局限性
- 研究仅纳入5例前列腺癌患者,需在更大队列中进一步验证。
- 尚未纳入适应性治疗策略及尿道剂量限制的考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to develop a framework for optimising prostate intensity-modulated radiotherapy (IMRT) based on patient-specific tumour biology, derived from multiparametric MRI (mpMRI). The framework included a probabilistic treatment planning technique in the effort to yield dose distributions with an improved expected treatment outcome compared with uniform-dose planning approaches. METHODS: IMRT plans were generated for five prostate cancer patients using two inverse planning methods: uniform-dose to the planning target volume and probabilistic biological optimisation for clinical target volume tumour control probability (TCP) maximisation. Patient-specific tumour location and clonogen density information were derived from mpMRI and geometric uncertainties were incorporated in the TCP calculation. Potential reduction in dose to sensitive structures was assessed by comparing dose metrics of uniform-dose plans with biologically-optimised plans of an equivalent level of expected tumour control. RESULTS: The planning study demonstrated biological optimisation has the potential to reduce expected normal tissue toxicity without sacrificing local control by shaping the dose distribution to the spatial distribution of tumour characteristics. On average, biologically-optimised plans achieved 38.6% (p-value: < 0.01) and 51.2% (p-value: < 0.01) reduction in expected rectum and bladder equivalent uniform dose, respectively, when compared with uniform-dose planning. CONCLUSIONS: It was concluded that varying the dose distribution within the prostate to take account for each patient's clonogen distribution was feasible. Lower doses to normal structures compared to uniform-dose plans was possible whilst providing robust plans against geometric uncertainties. Further validation in a larger cohort is warranted along with considerations for adaptive therapy and limiting urethral dose.
引用
- Her EJ, Haworth A, Reynolds HM, et al. Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI. Radiat Oncol. 2020. PMID: 32660504. doi:10.1186/s13014-020-01568-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。